Version July 2025
Ocular decongestant: Ophthalmic: Instill 1 to 2 drops in the affected eye(s) up to 4 times daily.
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
Refer to adult dosing.
Ocular decongestant (Visine products only): Children ≥6 years, and Adolescents: Ophthalmic: Refer to adult dosing.
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no adverse reactions listed in the manufacturer's labeling.
Disease-related concerns:
• Diabetes: Use with caution in patients with diabetes.
• Glaucoma: Use with caution in patients with narrow-angle glaucoma.
• Hyperthyroidism: Use with caution in patients with hyperthyroidism.
Dosage form specific issues:
• Benzalkonium chloride: Some products may contain benzalkonium chloride, which may be absorbed by soft contact lenses.
Other warnings/precautions:
• Accidental ingestion: Accidental ingestion by children of over-the-counter (OTC) imidazoline-derivative eye drops and nasal sprays may result in serious harm. Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children ≤5 years of age who had ingested even small amounts (eg, 1 to 2 mL). Contact a poison control center and seek emergency medical care immediately for accidental ingestion (FDA Drug Safety Communication 2012).
• Self-medication (OTC use): For ophthalmic use only. When used for self-medication, discontinue and contact a health care provider if eye pain, vision changes, continued redness, or eye irritation occurs or if condition worsens or persists >72 hours; do not use with contacts (remove prior to use). Do not use if solution changes color or becomes cloudy. Do not touch tip of container to any surface and replace cap after use. When using this product, pupils may become temporarily enlarged; overuse may cause more eye redness.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution, Ophthalmic, as hydrochloride:
Eye Drops: 0.05% (15 mL) [contains benzalkonium chloride, edetate (edta) disodium]
FT Eye Drops: 0.05% (15 mL) [contains benzalkonium chloride, edetate (edta) disodium]
FT Eye Drops Advanced Relief: Tetrahydrozoline hydrochloride 0.05% and polyethylene glycol 1% (15 mL) [contains benzalkonium chloride, edetate (edta) disodium]
Glitch Advanced Relief: Tetrahydrozoline hydrochloride 0.05% and polyethylene glycol 1% (15 mL [DSC]) [contains benzalkonium chloride, dextran, edetate (edta) disodium]
GoodSense Eye Drops: 0.05% (15 mL); Tetrahydrozoline hydrochloride 0.05%, dextran 0.1%, polyethylene glycol 1%, and povidone 1% (15 mL [DSC]) [contains benzalkonium chloride, edetate (edta) disodium]
GoodSense Eye Drops Adv Relief: Tetrahydrozoline hydrochloride 0.05%, dextran 0.1%, polyethylene glycol 1%, and povidone 1% (15 mL) [contains benzalkonium chloride, edetate (edta) disodium]
GoodSense Relief Eye Drops: Tetrahydrozoline hydrochloride 0.05% and zinc sulfate 0.25% (15 mL) [contains benzalkonium chloride, edetate (edta) disodium]
Visine A.C.: Tetrahydrozoline hydrochloride 0.05% and zinc sulfate 0.25% (15 mL) [contains benzalkonium chloride, edetate (edta) disodium]
Yes
Solution (Glitch Advanced Relief Ophthalmic)
0.05-1% (per mL): $0.53
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
For ophthalmic use only; wash hands prior to use. Do not touch tip of container to any surface, the eyelids, or the surrounding area. Remove contact lenses prior to administering products containing benzalkonium chloride; after instilling drops, wait at least 10 minutes before inserting contact lenses. Do not insert contacts if eyes are red.
Ophthalmic: Visine products only: For ophthalmic use only; wash hands prior to use. Do not touch tip of container to any surface, the eyelids, or the surrounding area. Remove contact lenses prior to administering products containing benzalkonium chloride; after instilling drops, wait at least 10 minutes before inserting contact lenses. Do not insert contacts if eyes are red.
Ocular decongestant: Relieves redness of the eye due to minor eye irritation and protects against further irritation; temporarily relieves burning and discomfort from dryness of the eye or exposure to wind and sun.
Visine may be confused with Visken
Accidental ingestion: Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children ≤5 years of age who have accidentally ingested even small amounts (eg, 1 to 2 mL) of imidazoline-derivative (ie, tetrahydrozoline, oxymetazoline, or naphazoline) eye drops or nasal sprays. Store these products out of reach of children at all times. Contact poison control or seek medical attention if accidental ingestion occurs.
None known.
There are no known significant interactions.
Stimulates alpha-adrenergic receptors in the arterioles of the conjunctiva to produce vasoconstriction
